Mesoblast Showcased at ASX Premier Investor Day Event
Mesoblast Limited presented at the ASX Investor Day in Melbourne, highlighting its transformation into a commercial-stage biotechnology company. The company outlined key value-creation priorities including expansion of its FDA-approved Ryoncil® therapy into adult acute graft-versus-host disease, advancement of rexlemestrocel-L for inflammatory chronic low back pain and cardiopulmonary indications, and disciplined capital deployment for commercial growth and late-stage development programs.